VBI Vaccines (VBIV) Reports Dosing of First GBM Patient in Phase 1/2a Clinical Study of VBI-1901
Tweet Send to a Friend
VBI Vaccines Inc. (NASDAQ: VBIV) today announced that the first patient has been dosed in a Phase 1/2a clinical study ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
